

NHI approves Biktarvy for reimbursement

02 October 2019 | News

Taiwan is on track to achieve the UNAIDS 90-90-90 goals



Gilead Sciences, Inc. has announced that Biktarvy® (bictegravir 50mg/emtricitabine 200 mg/tenofovir alafenamide 25 mg; BIC/FTC/TAF), a once-daily single tablet regimen (STR) for the treatment of HIV-1 infection in adults* will be made available via the National Health Insurance (NHI) scheme starting on 1 October 2019.

According to the Centers for Disease Control, there are more than 39,000 people living with HIV in Taiwan as of August 2019. Taiwan is on track to achieve the UNAIDS 90-90-90 goals to help end the HIV epidemic 90 percent of all people living with HIV will know their HIV status; 90 percent of all people with diagnosed HIV infection will receive sustained antiretroviral therapy; and 90 percent of all people.

"The reimbursement of Biktarvy will expand patient access to an innovative treatment for a broad range of patients, and support Taiwan's goal of treating the disease and helping to end HIV epidemic in Taiwan by 2030le receiving antiretroviral therapy will have viral suppression. Taiwan has made significant progress toward the 90-90-90 targets set by UNAIDS," said Pongo Peng, General Manager, Gilead Taiwan.

BIC/FTC/TAF was approved by the Taiwan Food and Drug Administration in January 2019 for the treatment of HIV-1 infection in adults without present or past evidence of viral resistance to integrase inhibitor class, emtricitabine or tenofovir.